Cipla has welcomed the firm’s first multi-regional licensing agreement in ophthalmology, after striking an exclusive licensing agreement bringing onboard Formosa Pharmaceuticals’ clobetasol propionate 0.05% ophthalmic suspension in 11 countries in Asia, Africa, and South America.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?